Table 1.

Baseline information of participants .

	Omalizumab treatment					Traditional pharmacotherapy	P-value
	2 weeks in advance (n=24)	2-4weeks in advance (n=20)	4-10weeks in advance (n=20)	In total (n=64)	p-value
Age	33.5 ± 2.7	34.9 ± 3.4	32.3 ± 3.8	33.5 ± 1.9	0.849	31.9 ± 2.8	0.589
Female (%)	11 (45.8%)	14 (70.0%)	9 (45.0%)	34 (53.1%)	0.189	16(50.0%)	0.830
Male (%)	13 (54.2%)	6 (30.0%)	11 (55.5%)	30 (46.9%)		16(50.0%)
Baseline CSMS	3.67[2.67,4.79]	4.50[3.04,5.00]	4.17[2.83,5.00]	4.00[2.83,4.96]	0.099	2.67[2.00,3.63]	0.000
Injection times
1	8 (33.3%)	6 (30.0%)	4 (20.0%)	18 (28.1%)
2	15 (62.5%)	9 (45.0%)	8 (40.0%)	32 (50.0%)
3	1 (4.2%)	5 (25.0%)	7 (35.0%)	13 (20.3%)
4	0	0	1 (5.0%)	1 (1.6%)